$Ensysce Biosciences(ENSC.US)$ Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program Ensysce Biosciences (NASDAQ: ENSC) has achieved a critical milestone in its opioid use disorder (OUD) program. The company has selected PF9001, a lead drug candidate designed to reduce abuse potential and improve safety, particularly with lower cardiovascular risks compared to traditional treatments. The candidate will proceed to Investigational New Drug (IND) enabling studies, backed...
Ensysce Biosciences股票討論區
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Ensysce Biosciences (NASDAQ: ENSC) has achieved a critical milestone in its opioid use disorder (OUD) program. The company has selected PF9001, a lead drug candidate designed to reduce abuse potential and improve safety, particularly with lower cardiovascular risks compared to traditional treatments. The candidate will proceed to Investigational New Drug (IND) enabling studies, backed...
新聞
Ensysce 生物科學繼續合作推動創新過量保護平台的臨床開發
生物科學研究所 (ENSYSCE) 已重新與生物科學合作,以推動其過量保護平台 PF614-MPAR 的臨床開發。這種創新的阿片類藥物產品旨在通過在攝入過多藥丸時關閉阿片類藥物釋放來防止過量,正在進行 1b 階段研究,以評估其有效性和...
.90 承諾??
苯甲· 4 分鐘前
...
苯甲· 2 分鐘前
會議重點介紹公司針對治療嚴重疼痛而設計的組合產品的非臨床計劃。FDA 就最終提交和批准新藥物申請(NDA)所需的非臨床研究提供了有用的反饋和建議。該指引將有助於簡化這種創新藥品製造商的開發計劃。
留在這裡
暫無評論